Overview

To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A clinical study to evaluate the efficacy and safety of tqc3564 tablets in the treatment of persistent allergic rhinitis. A total of 24 patients will be enrolled.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Montelukast